Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-09-25
2011-11-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S279100
Reexamination Certificate
active
08067442
ABSTRACT:
Compounds having the formula I wherein R1, R2a, R2b, R2c, R3, Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
REFERENCES:
patent: 2010/0021423 (2010-01-01), Brameld et al.
patent: WO00/09543 (2000-02-01), None
patent: WO01/85172 (2001-11-01), None
patent: 2009032116 (2009-03-01), None
patent: 2009032123 (2009-03-01), None
patent: 2009032125 (2009-03-01), None
patent: 2009039127 (2009-03-01), None
patent: 2009039134 (2009-03-01), None
patent: WO2009/039135 (2009-03-01), None
patent: 2009064848 (2009-05-01), None
patent: 2009064852 (2009-05-01), None
patent: WO2010/111436 (2010-09-01), None
patent: WO2010/111437 (2010-09-01), None
Chin Elbert
Li Jim
Talamas Francisco Xavier
Wang Beihan
Anderson Rebecca
Buckwalter Brian L.
Roche Palo Alto LLC
LandOfFree
Heterocyclic antiviral compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic antiviral compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic antiviral compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300244